XOMA Royalty (STU:X0M1) FCF Margin % : 48.22% (As of Jun. 2024)

View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. XOMA Royalty's Free Cash Flow for the three months ended in Jun. 2024 was €2.53 Mil. XOMA Royalty's Revenue for the three months ended in Jun. 2024 was €5.25 Mil. Therefore, XOMA Royalty's FCF Margin % for the quarter that ended in Jun. 2024 was 48.22%.

As of today, XOMA Royalty's current FCF Yield % is -2.61%.

The historical rank and industry rank for XOMA Royalty's FCF Margin % or its related term are showing as below:

STU:X0M1' s FCF Margin % Range Over the Past 10 Years
Min: -606.54 Med: -244.3 Max: 30.23
Current: -83.69

During the past 13 years, the highest FCF Margin % of XOMA Royalty was 30.23%. The lowest was -606.54%. And the median was -244.30%.

STU:X0M1's FCF Margin % is ranked better than
56.43% of 1049 companies
in the Biotechnology industry
Industry Median: -143.87 vs STU:X0M1: -83.69

XOMA Royalty FCF Margin % Historical Data

The historical data trend for XOMA Royalty's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty FCF Margin % Chart

XOMA Royalty Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-106.62

30.23

-10.02

-466.71

-382.01

XOMA Royalty Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-434.84	-252.83	-214.22	-333.11	48.22

Competitive Comparison of XOMA Royalty's FCF Margin %

For the Biotechnology subindustry, XOMA Royalty's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA Royalty's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's FCF Margin % distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's FCF Margin % falls into.

XOMA Royalty FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

XOMA Royalty's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.667	/	4.363
	=	-382.01 %

XOMA Royalty's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	2.533	/	5.253
	=	48.22 %

XOMA Royalty FCF Margin % Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA 0M26:UK

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines